The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1662
October 31, 2022
View Complete Issue         Table of Contents 2019 
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
October 31, 2022 (Issue: 1662)
A reader asked us to review use of the phosphodiesterase-5 (PDE5) inhibitor sildenafil for treatment of Alzheimer's disease (AD).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
Article code: 1662c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.